Plasma levels of antimicrobial peptide LL-37 as a biomarker of sleep quality in patients with obstructive sleep apnea: A clinical observational study
PLOS One · 2026
DOI: 10.1371/journal.pone.0355855 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift PLOS One, 2026. Verfasst von Takayuki Yamaguchi und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Behavioral Sleep Medicine, Iwate Medical University School of Medicine, Shiwa, Japan. Hauptthemen laut MEDLINE: Sleep Apnea, Obstructive, Antimicrobial Cationic Peptides, Sleep Quality. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Schlaf
Abstract (Originalsprache)
Objectives
Obstructive sleep apnea (OSA) is characterized by systemic inflammation, intermittent hypoxemia, and immune dysregulation and has been associated with increased susceptibility to viral infections. In this study, we aimed to evaluate plasma concentrations of the antimicrobial peptide cathelicidin LL-37 (pLL-37) in individuals with OSA.
Methods
The associations between pLL-37 levels, demographic characteristics, and polysomnographic (PSG) parameters were assessed in 58 individuals with OSA and 20 healthy controls. Participants were stratified into two groups stratified by apnea–hypopnea index (AHI): AHI < 15 and AHI ≥ 15. Multiple regression analysis was conducted to identify independent predictors of pLL-37.
Results
Significant negative correlations were observed between pLL-37 levels and age, percentage of Stage N1 sleep based on PSG data (%Stage N1), arousal index, AHI, and oxygen desaturation index. Conversely, significant positive correlations were identified between pLL-37 levels and %Stage N3, percentage of rapid eye movement sleep (%Stage REM), mean percentage of peripheral oxygen saturation (%SpO 2 mean), and %SpO 2 minimum. Mean pLL-37 level was significantly higher in the AHI < 15 group (75.3 ± 29.3 ng/L) than in the AHI ≥ 15 group (47.1 ± 18.3 ng/L). Multiple regression analysis identified %Stage N1 as an independent factor associated with pLL-37. Conclusions pLL-37 levels were significantly reduced in individuals with severe OSA than in healthy controls. %Stage N1 was independently associated with pLL-37 levels, suggesting a decline with worsening oxygen desaturation. These findings suggest pLL-37 may serve as a biomarker for sleep quality and the severity of impaired oxygenation during sleep with implications for immune vulnerability and infection risk in OSA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Behavioral Sleep Medicine, Iwate Medical University School of Medicine, Shiwa, Japan.
- Division of Information Sciences, Iwate Medical University, Shiwa, Japan.
- MSD/ Seimindo Sleep Labo Systems, Morioka, Iwate, Japan.
- Division of Internal Medicine, Yamaga Clinic, Takeda Healthcare Foundation, Aizu-Wakamatsu, Japan.
ORCID-Profile: Keisuke Hosokawa
Zitieren
APA
Yamaguchi, T., Hosokawa, K., Mineta, T., Hosokawa, R., Odawara, S., Chiba, R., Asanuma, K., Toyomaki, S., Sato, M., Takahashi, F., Sakurai, S., Takahashi, K., & Nishijima, T. (2026). Plasma levels of antimicrobial peptide LL-37 as a biomarker of sleep quality in patients with obstructive sleep apnea: A clinical observational study. PLOS One. https://doi.org/10.1371/journal.pone.0355855
Vancouver
Yamaguchi T, Hosokawa K, Mineta T, Hosokawa R, Odawara S, Chiba R, et al. Plasma levels of antimicrobial peptide LL-37 as a biomarker of sleep quality in patients with obstructive sleep apnea: A clinical observational study. PLOS One. 2026. doi:10.1371/journal.pone.0355855
BibTeX
@article{Yamaguchi2026,
author = {Yamaguchi, Takayuki and Hosokawa, Keisuke and Mineta, Takenori and Hosokawa, Rie and Odawara, Shiho and Chiba, Rie and Asanuma, Kazue and Toyomaki, Setsuko and Sato, Mitsuho and Takahashi, Fumiaki and Sakurai, Shigeru and Takahashi, Kazuhiro and Nishijima, Tsuguo},
title = {Plasma levels of antimicrobial peptide LL-37 as a biomarker of sleep quality in patients with obstructive sleep apnea: A clinical observational study},
journal = {PLOS One},
year = {2026},
doi = {10.1371/journal.pone.0355855}
}
EUVIMED